What is GRFS stock price today?

GRFS (Grifols SA ADR) stock is trading at $7.66 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is GRFS stock going up or down today?

GRFS stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy GRFS stock now?

The decision to buy GRFS depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is GRFS a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for GRFS based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is GRFS stock overvalued or undervalued?

GRFS currently trades at a P/E ratio of 10.52, which may suggest attractive valuation. Our DCF calculator provides intrinsic value estimates to help determine if GRFS is fairly priced.

What is GRFS's P/E ratio?

GRFS has a price-to-earnings (P/E) ratio of 10.52, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is GRFS's market cap?

GRFS (Grifols SA ADR) has a market capitalization of $5.08 billion, making it a small-cap stock.

What is GRFS's price to book ratio?

GRFS trades at a price-to-book (P/B) ratio of 0.83, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does GRFS pay dividends?

Yes, GRFS pays dividends with a current yield of 0.02%. Dividend payments provide income for investors in addition to potential stock price appreciation.

What is GRFS's dividend yield?

GRFS's dividend yield is 0.02%, calculated as annual dividends divided by the current stock price. This represents the annual return from dividends alone.

Is GRFS stock a good long-term investment?

GRFS's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is GRFS's revenue growth rate?

GRFS has shown revenue growth of -0.0% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Yes, GRFS is profitable with a profit margin of 0.1%. This indicates the company generates 0.1 cents of profit for every dollar of revenue.

What are the risks of investing in GRFS?

Key risks for GRFS include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does GRFS compare to its competitors?

Compare GRFS to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize GRFS's performance and positioning.

What is GRFS's stock price target for 2026?

Our AI model provides price targets for GRFS based on fundamental analysis: Bull case $9.95 (+30%), Base case $8.80 (+15%), Bear case $6.89 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about GRFS?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for GRFS. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is GRFS's next earnings report?

GRFS reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

GRFS - Grifols SA ADR

NYSE * Healthcare * Drug Manufacturers - General

$7.66

+$0.07 (+0.99%)

About Grifols SA ADR

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Price Chart

Loading chart...

GRFS Key Statistics

Market Cap

$5.08B

P/E Ratio

10.52

P/B Ratio

0.83

EPS

$0.71

Dividend Yield

0.02%

Revenue Growth

-0.0%

Profit Margin

0.1%

Employees

25,000

How GRFS Compares to Peers

GRFS has the lowest P/E ratio in Drug Manufacturers - General, suggesting it may be the most undervalued

GRFS is the smallest among peers, which may offer higher growth potential

P/E Rank

of 6

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
GRFS(This stock)	$5.08B	10.5	-0%	0.1%	-
LLYEli Lilly	$1.00T	40.0	1%	0.3%	vs LLY
JNJJohnson &	$549.25B	26.5	0%	0.2%	vs JNJ
PFEPfizer Inc	$147.50B	19.8	0%	0.1%	vs PFE
MRKMerck &	$297.02B	33.9	0%	0.1%	vs MRK
ABBVAbbVie Inc	$401.24B	110.8	0%	0.1%	vs ABBV

Grifols SA ADR Company Information

Headquarters: Parque Empresarial Can Sant Joan, Barcelona, Spain, 08174, undefined
Website: www.grifols.com
Sector: Healthcare
Industry: Drug Manufacturers - General

About Grifols SA ADR

Price Chart

GRFS Key Statistics

How GRFS Compares to Peers

Grifols SA ADR Company Information

Upcoming Events for GRFS